bioMérieux Partners with the Embassy of France in the United States against antimicrobial resistance.
bioMérieux co-hosted a conference with the Embassy of France in the United States on May 14 titled, “Rising to the Challenge: United Against Antimicrobial Resistance.” The conference featured renowned speakers from various sectors, including government agencies, academia, and industry, who discussed the latest global policies and initiatives to tackle antimicrobial resistance (AMR). His Excellency Laurent Bili, French Ambassador to the United States and Alexandre Mérieux, bioMérieux Chairman of the Board of Directors, gave opening remarks.
The joint conference shed light on the unique threat posed by AMR to humanity, highlighted the critical role of in vitro diagnostics, and outlined potential solutions to successfully adapt the United States funding and regulatory framework to advance policies to achieve better public health outcomes. Many conversations focused on the need to provide high medical-value diagnostic solutions to guide the effective and rational use of antibiotics.
“Antimicrobial resistance poses a significant and unique challenge to public health worldwide with bacterial infections being the second leading cause of death globally and resistant infections today1, said Alexandre Mérieux.. Collaborative efforts such as this conference are essential to address the issue effectively across sectors. We will remain steadfast in our commitment to advance diagnostic solutions that empower healthcare professionals to make informed treatment decisions to help sustain antibiotic efficacy for future generations."
bioMérieux experts and panelists also discussed the latest advancements in diagnostic technologies and solutions to combating this pressing global health threat, as well as groundbreaking insights and innovative approaches to AMR detection and surveillance.
“We talk about the problem, but what does success look like? We must utilize data and technology to understand AMR trends around the world. Fighting AMR also requires looking beyond the health space across the spectrum for solutions and identifying ways to work together.” – Loyce Pace, MPH Assistant Secretary for Global Affairs (OGA), US Department of Health & Human Services (HSS)
“Relying on the development of new antibiotics alone to fight AMR is not practical. We need to determine how to preserve the effectiveness of current and future antibiotics as long as possible – this is where in vitro diagnostics plays a key role. Healthcare systems need access to technology, as well as access and resources for stewardship teams - we have to make this standard.” – Dr. Charles K. Cooper, Executive Vice President Medical Affairs, Chief Medical Officer, bioMérieux
“Diagnostics guide the correct use of antibiotics. We need government-level intervention, and this is what the PASTEUR Act provides. The stewardship component of the PASTEUR Act pulls in the value of diagnostics as well. Health care providers need the right tools to adapt as new kinds of resistance emerge.” – John H. Rex, MD, FACP, Chief Medical Officer, F2G Ltd. I Operating Partner, Advent Life Sciences I Adjunct Professor of Medicine, McGovern Medical School.
bioMérieux is committed and ready to work with partners to develop solutions to slow the spread of AMR for improved patient outcomes.
